arrow

world health organization
H指数:0
被引数:869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020–2022: an, open-label, non-inferiority, randomised, controlled phase 2 trial

肌内注射与皮内注射分剂量灭活脊髓灰质炎病毒疫苗在莫桑比克,2020–2022年:一项开放标签、非劣效性、随机对照2期试验

2025-12-030
OAAI
Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022

新型口服脊髓灰质炎病毒2型疫苗接种运动的影响:尼日利亚2022年血清流行病学调查

VACCINE
IF3.5
2025-04-010
OAAI
Post-vaccination campaign evaluation of systemic and mucosal immunity of trivalent oral poliovirus vaccine in Karachi, Pakistan (2020-2021): a cross-sectional study

巴基斯坦卡拉奇 (2020-2021) 三价口服脊髓灰质炎病毒疫苗的全身和粘膜免疫接种后评估: 一项横断面研究

2025-02-010
PRE
Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021

巴布亚新几内亚cVDPV1暴发后脊髓灰质炎病毒血清学检测: 一项2020年2021年的横断面研究

2024-03-011
OAAI
One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh

一次或两次全剂量的灭活脊髓灰质炎病毒疫苗用于大龄婴儿的追赶疫苗接种: 孟加拉国的一项随机临床试验

2022-05-162
OAAI
Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children

尼日利亚儿童双价口服脊髓灰质炎病毒疫苗和灭活脊髓灰质炎病毒疫苗的随机对照临床试验

2020-11-241
OAAI
Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique

莫桑比克Mocuba减量单价2型口服脊髓灰质炎病毒疫苗的免疫原性

2020-11-127
OAAI
Impact of an antimicrobial stewardship intervention in India: Evaluation of post-prescription review and feedback as a method of promoting optimal antimicrobial use in the intensive care units of a tertiary-care hospital
2019-05-1424
PREAI